NEWS

NEWS

新闻资讯

Company news

Industry news

2025-07-09

Nanolattix Chairperson Dr. Zhican Qu Attends BIO 2025, Showcasing China's Biopharma Innovation

Nanolattix Chairperson Dr. Zhican Qu Attends BIO 2025, Showcasing China's Biopharma Innovation

Learn more

2025-07-09

Clinical Trial Recruitment for T320, a Novel TF-Targeting Anti-Cancer Drug

Clinical Trial Recruitment for T320, a Novel TF-Targeting Anti-Cancer Drug

Learn more

2025-07-09

Nanolattix’s T320-ADC Multi-Center Clinical Trials Initiated, Accelerating Development of Advanced Solid Tumor Therapies

Nanolattix’s T320-ADC Multi-Center Clinical Trials Initiated, Accelerating Development of Advanced Solid Tumor Therapies

Learn more

Nanolattix Chairwoman Dr. Zhuican Qu Makes Appearance at the 25th Annual Biotech in Europe Forum

Nanolattix Chairwoman Dr. Zhuican Qu Makes Appearance at the 25th Annual Biotech in Europe Forum

11

2025/10

Nanolattix Chairman Qu Zhican Visits China Energy Silk Road Chairman Cheng Yuan to Explore New Global Pathways for the Pharmaceutical and Health Industry

Nanolattix Chairman Qu Zhican Visits China Energy Silk Road Chairman Cheng Yuan to Explore New Global Pathways for the Pharmaceutical and Health Industry

10

2025/10

Nanolattix Chairman Qu Zhican Invited to Attend LSX World Congress in the USA

Nanolattix Chairman Qu Zhican Invited to Attend LSX World Congress in the USA

22

2025/09

Dr. Qu Zhican of Nanolattix Invited to Attend ADC & Novel Conjugates Partnering & Investment Summit in the U.S.

Dr. Qu Zhican of Nanolattix Invited to Attend ADC & Novel Conjugates Partnering & Investment Summit in the U.S.

22

2025/09

Nanolattix T320 Anti-Cancer Drug Project Successfully Secured Listing and Received Tens of Millions in Funding Support from Taiyuan City

Nanolattix T320 Anti-Cancer Drug Project Successfully Secured Listing and Received Tens of Millions in Funding Support from Taiyuan City

01

2025/09

Nanolattix T320 Anti-Cancer Drug Granted U.S. Patent!

Nanolattix T320 Anti-Cancer Drug Granted U.S. Patent!

01

2025/09